|Table of Contents|

The value of modified Glasgow prognostic score and systemic immune-inflammation index in predicting the prognosis of cervical cancer patients

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 08
Page:
1469-1474
Research Field:
Publishing date:

Info

Title:
The value of modified Glasgow prognostic score and systemic immune-inflammation index in predicting the prognosis of cervical cancer patients
Author(s):
LI Yubo1; LIANG Li2; WU Xiaojuan1; TIAN Qian1; HUA Yang3
1.Department of Obstetrics and Gynecology；2.Department of Gastroenterology;3.Department of Oncology,the Third People's Hospital of Yibin,Sichuan Yibin 644000,China.
Keywords:
modified Glasgow prognostic score; systemic immune-inflammation index; cervical cancer; prognosis; Kaplan-Meier method
PACS:
R737.33
DOI:
10.3969/j.issn.1672-4992.2024.08.018
Abstract:
Objective:To explore the value of modified Glasgow prognostic score (mGPS) and systemic immune-inflammation index (SII) in predicting the prognosis of patients with cervical cancer.Methods:A retrospective study was conducted on 143 patients with cervical cancer who treated in our hospital from 2010 to 2017.The complete medical records of all patients were collected and the patients were followed up until June 30,2023.Kaplan-Meier method was used to draw survival curves,Log-rank test,and Cox regression analysis were used to identify factors that affect patient prognosis.Results:The 3-year and 5-year survival rates of patients were 85.31% and 66.43%,respectively.The receiver operating curve (ROC) showed that mGPS,SII,albumin (ALB),lymphocytes (LYM),neutrophils (NEU),and C-reactive protein (CRP) were possible influencing factors for predicting the prognosis with area under the curve (AUC) at 0.821,0.867,0.875,0.885,0.835,and 0.696,respectively,with the optimal cut-off values at 0.5 points,34.65 g/L,1.38×109/L,5.55×109/L,7.25 mg/L,and 475×109/L,respectively.Cox regression analysis showed that mGPS,SII,and FIGO stage are prognostic factors for cervical cancer patients,with HR of 2.484 (GPS=1),7.096 (mGPS=2),0.121,9.507 (FIGO stage III),and 23.715 (FIGO stage IV),respectively (P＜0.05).Conclusion:mGPS,SII,and FIGO stage were important prognostic factors for cervical cancer patients.

References:

［1］李宏,高蓓,王媛.1990－2019年我国宫颈癌疾病负担变化趋势分析［J］.中国慢性病预防与控制,2022,30(9):672-675,681. LI H,GAO B,WANG Y.Trend analysis of disease burden of cervical cancer in China from 1990 to 2019［J］.Chin J Prev Control Chron Dis,2022,30(9):672-675,681.
［2］SURAN M.Why US cervical cancer survival rates haven't improved for decades［J］.JAMA,2022,327(20):1943-1945.
［3］ZHOU CK,LI CM,ZHENG YH,et al.Identification of pyroptosis-related signature for cervical cancer predicting prognosis［J］.Aging,2021,13(22):24795-24814.
［4］HUANG HP,LIU Q,ZHU LX,et al.Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer［J］.Sci Rep,2019,9(1):3284.
［5］YAMAMOTO T,KAWADA K,OBAMA K.Inflammation-related biomarkers for the prediction of prognosis in colorectal cancer patients［J］.Int J Mol Sci,2021,22(15):8002.
［6］TIAN BW,YANG YF,YANG CC,et al.Systemic immune-inflammation index predicts prognosis of cancer immunotherapy:systemic review and meta-analysis［J］.Immunotherapy,2022,14(18):1481-1496.
［7］WANG D,HU X,XIAO L,et al.Prognostic nutritional index and systemic immune-inflammation index predict the prognosis of patients with HCC［J］.J Gastrointest Surg,2021,25(2):421-427.
［8］林仲秋,王丽娟,刘龙阳.国际妇产科联盟2012宫颈癌诊治指南解读［J］.中国实用妇科与产科杂志,2013,29(5):323-325. LIN ZQ,WANG LJ,LIU LY.International Federation of Gynecology and Obstetrics,2012 interpretation of global guidance for cervical cancer prevention and control［J］.Chin J Pract Gynecol Obstet,2013,29(5):323-325.
［9］HACKER UT,HASENCLEVER D,BABER R,et al.Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial［J］.Ann Oncol,2022,33(7):685-692.
［10］WANG ZK,GUO ES,YANG B,et al.Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019:Cervical,ovarian and uterine cancer［J］.Gynecol Oncol,2021,163(2):358-363.
［11］OLAWAIYE AB,BAKER TP,WASHINGTON MK,et al.The new (Version 9) American Joint Committee on Cancer tumor,node,metastasis staging for cervical cancer［J］.CA Cancer J Clin,2021,71(4):287-298.
［12］WANG HY,LIU JC,YANG J,et al.A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer［J］.Front Immunol,2022,13:943389.
［13］ALWARAWRAH Y,KIERNAN K,MACIVER NJ.Changes in nutritional status impact immune cell metabolism and function［J］.Front Immunol,2018,9:1055.
［14］HUANG YH,CHEN Y,ZHU Y,et al.Postoperative systemic immune-inflammation index (SII):A superior prognostic factor of endometrial cancer［J］.Front Surg,2021,8:704235.
［15］LI JZ,CAO DH,HUANG Y,et al.The prognostic and clinicopathological significance of systemic immune-inflammation index in bladder cancer［J］.Front Immunol,2022,13:865643.
［16］张宇,汪亦民,薛英威.全身免疫炎症指数（SII）与胃癌患者临床病理因素及预后的相关性［J］.现代肿瘤医学，2021,29(03):441-445. ZHANG Y,WANG YM,XUE YW.Relationship between systemic immune-inflammatory index(SII) and clinical pathological features and prognosis in patients with gastric cancer［J］.Modern Oncology,2021,29(03):441-445.
［17］罗山晖,冯嵩崴,李青,等.mGPS预测宫颈癌术后患者预后的初步探讨［J］.现代肿瘤医学,2022,30(7):1279-1283. LUO SH,FENG SW,LI Q,et al.Preliminary study on mGPS to predict the prognosis of postoperative patients with cervical cancer［J］.Modern Oncology,2022,30(7):1279-1283.
［18］曹志文,宋东奎,魏晓松,等.术前全身免疫炎症指数对非肌层浸润性膀胱癌患者肿瘤复发的预测价值［J］.天津医药,2021,49(2):159-164. CAO ZW,SONG DK,WEI XS,et al.The predictive value of preoperative systemic immune-inflammation index for tumor recurrence in patients with non-muscular invasive bladder cancer［J］.Tianjin Med J,2021,49(2):159-164.
［19］LIU JJ,LI S,ZHANG S,et al.Systemic immune-inflammation index,neutrophil-to-lymphocyte ratio,platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab［J］.J Clin Lab Anal,2019,33(8):e22964.
［20］郭秀霞,陈忠萍.全身免疫炎症指数与宫颈癌患者预后的相关性［J］.山西卫生健康职业学院学报,2021,31(4):24-25. GUO XX,CHEN ZP.Correlation between systemic immune inflammation index and prognosis of cervical cancer patients［J］.J Shanxi Health Voc Coll,2021,31(4):24-25.
［21］GUO JF,LV WQ,WANG ZH,et al.Prognostic value of inflammatory and nutritional markers for patients with early-stage poorly-to moderately-differentiated cervical squamous cell carcinoma［J］.Cancer Control,2023,30:10732748221148913.
［22］PENG LP,LI J,LI XF.Prognostic value of neutrophil/lymphocyte,platelet/lymphocyte,lymphocyte/monocyte ratios and Glasgow prognostic score in osteosarcoma:A meta-analysis［J］.World J Clin Cases,2022,10(7):2194-2205.
［23］POLTERAUER S,GRIMM C,SEEBACHER V,et al.The inflammation-based Glasgow Prognostic Score predicts survival in patients with cervical cancer［J］.Int J Gynecol Cancer,2010,20(6):1052-1057.
［24］SEEBACHER V,STURDZA A,BERGMEISTER B,et al.Factors associated with post-relapse survival in patients with recurrent cervical cancer:the value of the inflammation-based Glasgow Prognostic Score［J］.Arch Gynecol Obstet,2019,299(4):1055-1062.
［25］MOHAMUD A,HOGDALL C,SCHNACK T.Prognostic value of the 2018 FIGO staging system for cervical cancer［J］.Gynecol Oncol,2022,165(3):506-513.
［26］QIN FY,PANG HT,YU T,et al.Treatment strategies and prognostic factors of 2018 FIGO stage IIIc cervical cancer:A review［J］.Technol Cancer Res Treat,2022,21:15330338221086403.

Memo

Memo:
四川省卫健委科研课题（编号：21PJ541）；四川省宜宾市卫健委项目(编号：2019YW010)
Last Update: 1900-01-01